** Shares of rare neurological disease-focused pharma company Harmony Biosciences HRMY.O up 3.7% at $35.44 premarket
** Company posts Q4 adj profit of $1.08 per share, beating analysts' estimates of 74 cents per share, according to data compiled by LSEG
** Co records Q4 sales of sleep disorder drug, Wakix, at $201.3 million, beating analysts' estimates of $200 million
** Expects 2025 net product revenue of $820 million to $860 million, midpoint of which is below analysts' estimates of $848 million
** In the last 12 months, HRMY rose 4.7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。